Curis (FRA:CUS0) Valuation Rank


FRA:CUS0 Curis Inc FRA:CUS0
59 GF Score
Price €0.40
GF Value €0.79
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Curis Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Curis Valuation Rank Related Terms

FRA:CUS0
59GF Score
Curis Inc FRA:CUS0
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Curis (FRA:CUS0) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be undervalued. The current stock price of €0.40 is trading 49.4% below its estimated GF Value™ of €0.79. GuruFocus considers Curis to be Possible Value Trap.

Key valuation signals for FRA:CUS0:

  • Valuation Rank:
  • GF Value™: €0.79 vs. price of €0.40 (49.4% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
59GF Score

Get the complete analysis for FRA:CUS0

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price
€0.79
GF Value